XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning

"SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting-no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap stalwarts like Eli Lilly and Company () and Merck & Co. (), mid-cap specialty pharmaceutical companies, and smaller biotech names focused on niche therapeutics."

"The ETF's return engine is straightforward: it captures the cash flows and appreciation potential of pharmaceutical businesses across the capitalization spectrum. Unlike healthcare sector funds that blend device makers, insurers, and care providers, XPH concentrates 98.4% of assets in healthcare, with the overwhelming majority in drug development and commercialization. Investors gain exposure to revenue from patent-protected drugs, biosimilar competition dynamics, and the pipeline risk-reward of clinical trials. The fund does not use derivatives or leverage-what you see in the holdings is what drives performance."

"XPH's one-year return of 29.44% significantly outpaced SPDR S&P 500 ETF Trust (NYSEARCA:SPY)'s 12% gain, reflecting a strong rotation into pharmaceutical stocks driven by renewed investor appetite for drug development pipelines and pricing power narratives. That momentum is real, but it represents a cyclical tailwind rather than a structural trend. Zooming out tells a more cautionary story. Over five years, XPH gained just 10.49% against the broader market's 74.77%-a gap driven by the dominance of technology and growth stocks that pharmaceutical names could not match."

SPDR S&P Pharmaceuticals ETF (XPH) holds 57 relatively evenly weighted positions to limit concentration risk from the largest healthcare names. The fund concentrates 98.4% of assets in healthcare, primarily in drug development and commercialization, and does not use derivatives or leverage. Holdings span large-cap pharmaceutical stalwarts, mid-cap specialty companies, and smaller biotech firms focused on niche therapeutics. Short-term performance has recently been strong, with a one-year return of 29.44%, but longer-term returns lag broader equity benchmarks: five-year and ten-year figures show underperformance versus the S&P 500, positioning XPH as a diversifier.

Read at 24/7 Wall St.